Skip to main content
Vitrolife logo

Vitrolife — Investor Relations & Filings

Ticker · VITR ISIN · SE0011205202 LEI · 5493001WDZMONMSPPR49 ST Manufacturing
Open in API
Filings indexed 656 across all filing types
Latest filing 2018-10-09 Board/Management Inform…
Country SE Sweden
Listing ST VITR

About Vitrolife

https://www.vitrolife.com/

Vitrolife is a global company focused on reproductive health, providing medical devices and genetic testing services primarily to In Vitro Fertilization (IVF) clinics. The company develops, produces, and markets a comprehensive portfolio of products and solutions that support the entire assisted reproduction treatment journey, from oocyte retrieval and sperm preparation to fertilization, embryo culture, evaluation, transfer, and cryopreservation. With a strong emphasis on quality control, innovation, and clinical support, Vitrolife aims to improve treatment outcomes and operational efficiency for its partners. The company also offers educational resources and training for professionals through its Vitrolife Academy.

Recent filings

Filing Released Lang Actions
Election committee for Vitrolife AB (publ)
Board/Management Information Classification · 99% confidence The document explicitly discusses the appointment of members to the company's election committee for the upcoming Annual General Meeting (AGM) in 2019. It names the representatives and confirms the date of the AGM. This content directly relates to the preparatory and administrative aspects surrounding the AGM, which aligns best with the 'AGM Information' category (AGM-R). It is not a full report (10-K, IR), a management change (MANG), or a proxy solicitation (PSI), but rather specific information regarding the AGM process itself.
2018-10-09 English
Vitrolife ingår partnerskap med Illumina om preimplantatorisk genetisk testning
Regulatory Filings Classification · 90% confidence The document is a press release dated October 2, 2018, announcing a significant licensing and commercialization agreement between Vitrolife AB and Illumina Inc. regarding preimplantation genetic testing (PGT). It details financial terms (USD 13 million upfront payment, future milestones), expected financial impact (EBITDA, revenue contribution), and mentions an upcoming capital markets day. This type of announcement, detailing a major strategic transaction (partnership/licensing) and its financial implications, does not fit neatly into the specific financial report categories (10-K, IR, ER) or governance/shareholder event categories (AGM-R, DEF 14A). It is a material corporate event announcement. Since it is not a standard regulatory filing form (like 10-K or MRQ) but a significant corporate update, the most appropriate category is the general 'Regulatory Filings' (RNS) as a catch-all for material, non-standard announcements, or potentially 'Capital/Financing Update' (CAP) due to the large payment and future consideration, but RNS is safer for general press releases about strategic deals. Given the options, and that it is a press release about a major business transaction, RNS (Regulatory Filings/General Announcement) is the best fit, as it is not a specific financial report or management disclosure defined elsewhere.
2018-10-02 Swedish
Vitrolife partners with Illumina on preimplantation genetic testing
Regulatory Filings Classification · 94% confidence The document is a press release dated October 2, 2018, announcing a significant business development: Vitrolife entering into a License and Commercialisation Agreement with Illumina regarding preimplantation genetic testing (PGT). This involves exclusive distribution rights, development plans, and financial considerations (a USD 13 million payment). This type of announcement, detailing a major strategic partnership or transaction that impacts the business structure and future performance, fits best under Capital/Financing Update (CAP) if it involves raising capital or major asset changes, or potentially Regulatory Filings (RNS) if it's a general market disclosure. However, since it details a major commercial agreement and associated financial terms, it is a significant corporate action. Given the options, it is not an earnings release (ER), an interim report (IR), or a formal regulatory filing like a 10-K. It is a specific announcement about a major business transaction. While it mentions a future Capital Markets Day, the core content is the partnership agreement itself. This type of material corporate transaction announcement often falls under general regulatory disclosure or, if it involves significant capital structure changes or fundraising, CAP. Since it's a commercial agreement with a one-time payment and purchase commitments, it relates to corporate financing/structure changes. However, the most fitting general category for a significant, non-standard corporate announcement that isn't explicitly covered by other categories (like M&A, DIV, ER) and is presented as a press release is often RNS (Regulatory Filings) as a catch-all for material non-standard disclosures, or potentially TAR if it were an acquisition/merger. Since it is a licensing/distribution agreement, RNS is the safest classification for a material press release that doesn't fit the other specific financial/governance codes. Given the options, and recognizing it's a material corporate event disclosure, RNS is the appropriate fallback, although CAP is a possibility if the focus was purely on the financing aspect of the deal. I will classify it as RNS as it is a general regulatory announcement via press release.
2018-10-02 English
Vitrolife strengthens organization in business development
Board/Management Information Classification · 99% confidence The document is a press release announcing a change in senior management and board composition: 'Vitrolife has appointed the Board member Fredrik Mattsson as head of the newly established New Business and Strategic Development function' and 'Fredrik Mattsson is stepping down as a Board member... and Henrik Blomquist... will assume the role of co-opted Board member'. This directly relates to changes in the company's board of directors or senior management. Therefore, the appropriate classification is Board/Management Information (MANG). The document length is short, but it is an announcement of an event, not an announcement about the publication of a separate, larger report.
2018-09-12 English
Vitrolife förstärker organisationen inom affärsutveckling
Board/Management Information Classification · 99% confidence The document is a press release dated September 12, 2018, announcing a change in senior personnel: Fredrik Mattsson is appointed to a new role (Head of New Business and Strategic Development) and resigns from the Board of Directors, while Henrik Blomquist joins the board as an adjunct member. This directly relates to changes in the company's senior management and board structure. This aligns perfectly with the definition for Board/Management Information (MANG). It is not an earnings release (ER), a formal annual report (10-K), or a general regulatory filing (RNS), as the content is highly specific to management appointments.
2018-09-12 Swedish
Interim / Quarterly Report 2018
Interim / Quarterly Report Classification · 100% confidence The document is titled 'delårsrapport januari-juni 2018' (Interim Report January-June 2018) for Vitrolife AB. It contains comprehensive financial statements, segment reporting, cash flow analysis, and management commentary for the first half of the fiscal year. It is a substantive financial report rather than an announcement or a summary, fitting the definition of an Interim/Quarterly Report. H1 2018
2018-07-13 Swedish

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.